https://www.taxtmi.com/news?id=30898 An investigator-initiated, multi-centre, randomized, open-label trial (SirPAD) completed enrolment of over 1,250 patients to compare the MagicTouch PTA sirolimus-coated balloon with uncoated balloons in peripheral artery disease. Patients will be followed for 12 months to assess the primary outcome of major adverse limb events (MALE). The study is designed as a non-inferiority trial to POBA with an exploratory assessment of superiority, and final results are expected in early to mid-2026. en-us Tue, 21 Jan 2025 11:01:03 +0530 Tue, 21 Jan 2025 11:01:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=30898 An investigator-initiated, multi-centre, randomized, open-label trial (SirPAD) completed enrolment of over 1,250 patients to compare the MagicTouch PTA sirolimus-coated balloon with uncoated balloons in peripheral artery disease. Patients will be followed for 12 months to assess the primary outcome of major adverse limb events (MALE). The study is designed as a non-inferiority trial to POBA with an exploratory assessment of superiority, and final results are expected in early to mid-2026. News - Tue, 21 Jan 2025 11:01:03 +0530 https://www.taxtmi.com/news?id=30898